Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2020 | Cost-effectiveness of CAR T-cell therapy

Carin Al Uyl-de Groot • 12 Feb 2020
CAR-T Meeting 2020
Acute Lymphoblastic Leukemia Diffuse Large B-Cell Lymphoma Leukemia Lymphoma Non-Hodgkin Lymphoma CAR-T

Carin Al Uyl-de Groot, PhD, Erasmus University Rotterdam, Rotterdam, The Netherlands, discusses the evaluation of the cost-effectiveness of CAR T-cell therapy for pediatric acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.

More from Carin Al Uyl-de Groot

0:54
Pre- and post-CAR T-cell therapy costs
Carin Al Uyl-de Groot • 30 Jan 2020

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
5:14
Is transplantation and chemotherapy still necessary for all patients with Ph+ ALL?
Robin Foà • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals